Azacitidine

Generic Name
Azacitidine
Brand Names
Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
320-67-2
Unique Ingredient Identifier
M801H13NRU
Background

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...

Indication

Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...

Associated Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
Associated Therapies
-
Clinical Trials
Related News

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

First Posted Date
2008-08-26
Last Posted Date
2012-04-23
Lead Sponsor
S*BIO
Target Recruit Count
85
Registration Number
NCT00741234
Locations
🇸🇬

National University Hospital, Singapore, Singapore

🇸🇬

Singapore General Hospital, Singapore, Singapore

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: azacytidine
First Posted Date
2008-08-21
Last Posted Date
2013-04-10
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
47
Registration Number
NCT00739388
Locations
🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

🇨🇭

Spitalzentrum Biel, Biel, Switzerland

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

and more 8 locations

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

First Posted Date
2008-08-06
Last Posted Date
2008-08-06
Lead Sponsor
Kansas City Veteran Affairs Medical Center
Target Recruit Count
40
Registration Number
NCT00728520
Locations
🇺🇸

Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: 5-azacytidine
First Posted Date
2008-07-24
Last Posted Date
2016-03-02
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
16
Registration Number
NCT00721214
Locations
🇺🇸

Massey Cancer Center / Virginia Commonwealth University, Richmond, Virginia, United States

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

First Posted Date
2008-04-25
Last Posted Date
2015-05-08
Lead Sponsor
Mirati Therapeutics Inc.
Target Recruit Count
6
Registration Number
NCT00666497
Locations
🇬🇧

St. Bartholomews Hospital, London, United Kingdom

🇨🇦

Diamond Centre, Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada

🇨🇦

Jewish General Hospital, Montreal, Quebec, Canada

and more 5 locations

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2008-04-15
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
133
Registration Number
NCT00658814
Locations
🇺🇸

Salina Regional Health Center, Salina, Kansas, United States

🇺🇸

Saint Ann's Hospital, Westerville, Ohio, United States

🇺🇸

Cancer Center of Kansas - Salina, Salina, Kansas, United States

and more 174 locations

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

First Posted Date
2008-04-04
Last Posted Date
2019-11-19
Lead Sponsor
Celgene
Target Recruit Count
31
Registration Number
NCT00652626
Locations
🇺🇸

Palm Springs Research Institute, Hialeah, Florida, United States

🇺🇸

Sutter East Bay Hospitals, Berkeley, California, United States

🇺🇸

Pharma Resource, East Providence, Rhode Island, United States

and more 8 locations

Ph II Study of Azacitidine in Myelofibrosis

Phase 2
Completed
Conditions
Myelofibrosis
Interventions
Drug: Azacitidine
First Posted Date
2007-12-07
Last Posted Date
2012-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
34
Registration Number
NCT00569660
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

First Posted Date
2007-12-06
Last Posted Date
2012-08-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT00569010
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

First Posted Date
2007-09-14
Last Posted Date
2013-02-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT00529022
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy